Veracyte, Inc. Appoints Dr. Neil M. Barth as Chief Medical Officer
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointment of Neil M. Barth, M.D., F.A.C.P., as chief medical officer, effective immediately.
"We are delighted to welcome a medical leader of Dr. Barth's caliber to our executive team," said Bonnie H. Anderson, Veracyte's president and chief executive officer. "Our Afirma® solution is already becoming a new standard of care in thyroid cancer diagnosis and we have recently launched our Percepta™ Bronchial Genomic Classifier into pulmonology, our second clinical area. Dr. Barth's exceptional clinical leadership and experience will be invaluable as we continue our momentum with genomic tests that help reduce unnecessary surgeries in disease diagnosis and lower healthcare costs."
Dr. Barth has more than 30 years of experience providing and directing patient care for healthcare-provider organizations and diagnostics companies. Most recently, he served as chief medical officer for Agendia NV, a molecular diagnostics company focused on oncology, where he guided the company's medical strategic direction, quality initiatives, and interface with regulators and payers. Prior to that, Dr. Barth served as chief medical officer for Ambry Genetics, a clinical genetics diagnostics company.
Dr. Barth's patent-care experience includes 30 years as president and medical director for Newport Pacific Medical Associates, a large hematology-oncology medical practice he founded in 1982. Concurrently, he served in various roles, including executive medical director and chief of staff, at Orange County, Calif.-based Hoag Memorial Presbyterian Hospital and Hoag Family Cancer Institute.
See more from Benzinga
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
